TD Asset Management Inc Purchases 105,930 Shares of Cellebrite DI Ltd. $CLBT

Key Points

• TD Asset Management Inc significantly increased its stake in Cellebrite DI Ltd. by 99.6%, acquiring 105,930 shares during the 2nd quarter, bringing their total ownership to 212,236 shares valued at approximately $3.4 million.
• Cellebrite DI reported a quarterly earnings beat with $0.12 earnings per share, surpassing analyst expectations and showing an 18.4% increase in revenue compared to the previous year.
• The stock currently has a consensus rating of “Moderate Buy” from analysts, with a target price averaging around $21.75, despite a recent downgrade from Needham & Company LLC.

TD Asset Management Inc increased its position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 99.6% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 212,236 shares of the company's stock after acquiring an additional 105,930 shares during the quarter. TD Asset Management Inc owned about 0.09% of Cellebrite DI worth $3,396,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of CLBT. T. Rowe Price Investment Management Inc. bought a new position in Cellebrite DI during the 1st quarter worth approximately $60,939,000. Invesco Ltd. boosted its stake in Cellebrite DI by 122.1% during the 1st quarter. Invesco Ltd. now owns 3,296,079 shares of the company's stock worth $64,043,000 after acquiring an additional 1,811,757 shares during the last quarter. Bank of New York Mellon Corp bought a new position in Cellebrite DI during the 1st quarter worth approximately $22,428,000. Royal Bank of Canada boosted its stake in Cellebrite DI by 11,705.0% during the 1st quarter. Royal Bank of Canada now owns 824,226 shares of the company's stock worth $16,015,000 after acquiring an additional 817,244 shares during the last quarter. Finally, Nuveen LLC bought a new position in Cellebrite DI during the 1st quarter worth approximately $15,031,000. Institutional investors own 45.88% of the company's stock.

Cellebrite DI Stock Down 0.7%

NASDAQ CLBT opened at $18.05 on Tuesday. Cellebrite DI Ltd. has a 12-month low of $13.10 and a 12-month high of $26.30. The company has a market capitalization of $4.32 billion, a PE ratio of -23.75, a price-to-earnings-growth ratio of 3.30 and a beta of 1.29. The firm's 50 day moving average is $17.32 and its 200-day moving average is $16.91.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last posted its quarterly earnings data on Thursday, August 14th. The company reported $0.12 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.11 by $0.01. Cellebrite DI had a negative net margin of 34.56% and a positive return on equity of 23.92%. The company had revenue of $113.28 million for the quarter, compared to the consensus estimate of $112.33 million. During the same period last year, the company earned $0.10 earnings per share. The firm's revenue was up 18.4% compared to the same quarter last year. Cellebrite DI has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, sell-side analysts expect that Cellebrite DI Ltd. will post 0.3 EPS for the current year.

Analysts Set New Price Targets

CLBT has been the topic of several research analyst reports. JPMorgan Chase & Co. raised their target price on shares of Cellebrite DI from $20.00 to $23.00 and gave the stock an "overweight" rating in a report on Wednesday, September 24th. Weiss Ratings restated a "sell (d+)" rating on shares of Cellebrite DI in a report on Wednesday, October 8th. Needham & Company LLC dropped their target price on shares of Cellebrite DI from $24.00 to $18.00 and set a "buy" rating on the stock in a report on Thursday, August 14th. Wall Street Zen upgraded shares of Cellebrite DI from a "hold" rating to a "buy" rating in a report on Friday, September 26th. Finally, Lake Street Capital dropped their target price on shares of Cellebrite DI from $24.00 to $22.00 and set a "buy" rating on the stock in a report on Friday, August 15th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $21.75.

Cellebrite DI Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.